• The US Supreme Court has restored mail access to the abortion pill mifepristone.
• Justice Samuel Alito issued a temporary stay on a 5th Circuit ruling restricting mail delivery.
• This order allows mifepristone to be prescribed via telehealth until at least May 11.
• The decision comes amid ongoing litigation regarding abortion access in several states.
• Most abortions in the US are obtained through medication, primarily utilizing mifepristone.

The US Supreme Court has temporarily restored mail delivery of mifepristone, a widely used abortion pill, reversing a recent ruling from the 5th Circuit Court of Appeals that had imposed stricter access requirements. This decision allows women to obtain the medication through pharmacies or via mail without an in-person doctor's visit, at least until May 11, as the court reviews the ongoing legal considerations concerning the drug's use, according to Reuters and CBS News.

The Supreme Court's order, issued by Justice Samuel Alito, came in response to emergency appeals filed by the drug's manufacturers, Danco Laboratories and GenBioPro, seeking to maintain access to mifepristone as litigation unfolds. Alito's stay momentarily halts the 5th Circuit's decision which mandated that patients obtain the pill in person, a requirement that had been relaxed during the COVID-19 pandemic and subsequently overturned by the FDA, according to South China Morning Post and Le Monde.

The impact of these developments is significant, as medication abortions, which predominantly involve mifepristone and misoprostol, account for over 60% of abortions performed in the United States. The legal landscape for abortion access continues to shift following the 2022 Supreme Court decision that overturned Roe v. Wade, leading to various states enacting stricter abortion laws. Louisiana, which filed the lawsuit prompting the recent appellate court ruling, maintains some of the nation’s strictest anti-abortion regulations, asserting that the availability of mifepristone challenges their laws, as reported by NPR and Le Monde.

As the situation develops, both sides are required to file legal briefs by May 7, with the Supreme Court expected to make further decisions regarding mifepristone's access following these submissions. This ongoing battle over the abortion pill is critical for many women seeking healthcare, particularly in states with heightened restrictions, as highlighted by the implications of the 5th Circuit ruling on the healthcare economy and patient access, according to Reuters, CBS News, and South China Morning Post.